Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [2] - Established in 1981, the company has become a reliable contract manufacturer for major international healthcare and medical device companies [2] - The company's revenue is derived from two main segments: manufacturing and selling disposable medical device components, and providing mold-making services [2] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, showing a year-on-year increase of 61% [1] - The gross profit margin stood at 2.18%, while the debt-to-asset ratio was 75.71% [1] Market Position and Valuation - 加和国际控股's price-to-earnings (P/E) ratio is -6.88, ranking 85th in the industry, compared to the average P/E ratio of -2.68 for the healthcare equipment and services sector [1] - The company has experienced a cumulative decline of 11.19% over the past month and a 28.25% decline year-to-date, underperforming the Hang Seng Index, which has risen by 19.78% [1] - Currently, there are no investment rating recommendations from institutions for 加和国际控股 [1] Industry Context - The healthcare equipment and services industry has an average P/E ratio of -2.68, with a median of 1.17 [1] - Other companies in the industry include 巨星医疗控股 (02393.HK) with a P/E of 0.28, 京玖康疗 (00648.HK) at 0.38, 医汇集团 (08161.HK) at 1.96, 环球医疗 (02666.HK) at 5.24, and 瑞慈医疗 (01526.HK) at 5.4 [1]

Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [3] - The company was established in 1981 and has become a reliable contract manufacturer for major international healthcare and medical device companies [3] - The revenue streams of the company include manufacturing and selling disposable medical device components and providing mold-making services [3] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [2] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, which is a year-on-year increase of 61% [2] - The gross profit margin stands at 2.18%, while the debt-to-asset ratio is 75.71% [2] Market Position and Valuation - Over the past month, 加和国际控股 has experienced a cumulative decline of 10.34%, and a year-to-date decline of 26.55%, underperforming the Hang Seng Index, which has increased by 18.2% [2] - The company's price-to-earnings (P/E) ratio is -7.04, ranking 83rd in the industry, while the average P/E ratio for the healthcare equipment and services industry is -21.64 [2] - Other companies in the same sector have P/E ratios such as 巨星医疗控股 at 0.33, 京玖康疗 at 0.38, 永胜医疗 at 4.25, 环球医疗 at 4.64, and 瑞慈医疗 at 5.2 [2]

Company Overview - 加和国际控股有限公司 is a contract manufacturer based in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [2] - Established in 1981, the company has become a reliable contract manufacturer for major international healthcare and medical device companies [2] - The company's revenue is derived from two main segments: manufacturing and selling injection-molded plastic components for disposable medical devices, and providing mold-making services [2] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, which is a 61% increase compared to the previous period [1] - The gross profit margin stands at 2.18%, with a debt-to-asset ratio of 75.71% [1] Market Position and Valuation - 加和国际控股's price-to-earnings (P/E) ratio is -6.71, ranking 83rd in its industry, while the average P/E ratio for the healthcare equipment and services sector is -21.39 [1] - The company has underperformed the Hang Seng Index, with a cumulative decline of 29.94% year-to-date, compared to the index's increase of 20.55% [1] - Currently, there are no investment rating recommendations from institutions for 加和国际控股 [1] Industry Context - The healthcare equipment and services industry has an average P/E ratio of -21.39, with a median of 0.3 [1] - Competitors in the industry include other companies with varying P/E ratios, such as 巨星医疗控股 at 0.22, 京玖康疗 at 0.38, and 永胜医疗 at 3.83 [1]

Company Overview - 加和国际控股有限公司 is a contract manufacturer headquartered in Singapore, specializing in the production and sale of disposable medical devices and injection-molded plastic components, as well as providing mold-making services [3] - The company was established in 1981 and has become a reliable contract manufacturer for major international healthcare and medical device companies [3] - The revenue streams of the company include manufacturing and selling injection-molded plastic components for disposable medical devices and providing mold-making services [3] Financial Performance - As of December 31, 2024, 加和国际控股 reported total revenue of 55.6565 million yuan, representing a year-on-year growth of 14.33% [1] - The company recorded a net profit attributable to shareholders of -14.0006 million yuan, which is a 61% increase compared to the previous year [1] - The gross profit margin stands at 2.18%, while the debt-to-asset ratio is 75.71% [1] Market Position and Valuation - Currently, there are no institutional investment ratings for 加和国际控股 [2] - The company's price-to-earnings (P/E) ratio is -7.04, ranking 82nd in the industry, while the average P/E ratio for the healthcare equipment and services industry is -20.22 [2] - Other companies in the industry have varying P/E ratios, with 巨星医疗控股 at 0.22, 京玖康疗 at 0.38, 永胜医疗 at 3.78, 环球医疗 at 4.64, and 瑞慈医疗 at 5.45 [2]